Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels

被引:19
|
作者
Xu, Jie [1 ,2 ,3 ]
Hao, Xiwa [1 ,2 ,3 ,6 ]
Zhan, Rui [2 ,3 ,4 ,5 ]
Jiang, Xue [2 ,3 ,4 ,5 ]
Jin, Aoming [1 ,2 ,3 ]
Xue, Jing [2 ,3 ,4 ,5 ]
Cheng, Aichun [1 ,2 ,3 ]
Liu, Jiewen [1 ,2 ,3 ]
Lin, Jinxi [7 ]
Meng, Xia [1 ,2 ,3 ]
Li, Hao [1 ,2 ,3 ]
Zheng, Lemin [2 ,3 ,4 ,5 ]
Wang, Yongjun [1 ,2 ,3 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China
[2] Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
[3] Capital Med Univ, Adv Innovat Ctr Human Brain Protect, Beijing, Peoples R China
[4] Peking Univ, Hlth Sci Ctr, Minist Educ, Inst Cardiovasc Sci, Beijing, Peoples R China
[5] Peking Univ, Hlth Sci Ctr, Inst Syst Biomed, Sch Basic Med Sci,Key Lab Mol Cardiovasc Sci,Mini, Beijing, Peoples R China
[6] Baotou Cent Hosp, Dept Neurol, Baotou, Inner Mongolia, Peoples R China
[7] McGill Univ, Montreal, PQ, Canada
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
apolipoprotein; cardiovascular disease; inflammation; ischemic stroke; phospholipid; ACUTE ISCHEMIC-STROKE; CARDIOVASCULAR RISK; DISEASE; EVENTS;
D O I
10.1161/STROKEAHA.121.034924
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Lp(a) (lipoprotein(a)) contributes to cardiovascular disease mainly through proatherogenic and proinflammatory effects. Here, we aimed to evaluate whether a residual stroke risk of Lp(a) would remain when the LDL-C (low-density lipoprotein cholesterol) and inflammatory levels are maintained low. Methods: This prospective cohort study included 9899 patients with ischemic stroke or transient ischemic attack from the Third China National Stroke Registry who had measurements of plasma Lp(a) and were followed up for 1 year. Cutoffs were set at the 50 mg/dL for Lp(a). LDL-C was corrected for Lp(a)-derived cholesterol (LDL-Cc [LDL-C corrected]) and cutoffs were set at 55 and 70 mg/dL.The threshold values of IL-6 (interleukin 6) and hsCRP (high-sensitive C-reactive protein) were the median 2.65 ng/L and 2 mg/L. Multivariable-adjusted hazard ratio (HR) were calculated using Cox regression models for each category to investigate the associations of Lp(a) with stroke recurrence within 1 year. Results: Among all patients, those with Lp(a) >= 50 mg/dL were at higher stroke recurrence risk than those with Lp(a) <50 mg/dL (11.5% versus 9.4%; adjusted HR, 1.20 [95% CI, 1.02-1.42]). However, the risk associated with elevated Lp(a) was attenuated in patients with LDL-Cc <55 mg/dL (high Lp(a) versus low Lp(a): 8.9% versus 9.0%; adjusted HR, 0.92 [95% CI, 0.65-1.30]) or IL-6 <2.65 ng/L (9.0% versus 7.8%; adjusted HR, 1.14 [95% CI, 0.87-1.49]). Notably, in the group with both low LDL-Cc and inflammation levels, the rate of patients with high Lp(a) did not significantly different from the rate of patients with low Lp(a; LDL-Cc <55 mg/dL and IL-6 <2.65 ng/L: 6.2% versus 7.1%; adjusted HR, 0.86 [95% CI, 0.46-1.62]; LDL-Cc <55 mg/dL and hsCRP <2 mg/L: 7.7% versus 7.6%; adjusted HR, 0.97 [95% CI, 0.57-1.66]). However, there was no interaction between the LDL-Cc, IL-6, hsCRP, and Lp(a) levels on stroke recurrence risk. Conclusions: Increased Lp(a) was significantly associated with stroke recurrence risk in patients with ischemic stroke/transient ischemic attack. However, at low LDL-Cc or IL-6 levels, the elevated Lp(a) -associated stroke recurrence risk was attenuated in a secondary prevention setting.
引用
收藏
页码:2504 / 2511
页数:8
相关论文
共 50 条
  • [41] Zoledronic acid increases high-density lipoprotein cholesterol (HDL-C) and decreases low-density lipoprotein cholesterol (LDL-C) in multiple myeloma patients
    Gozzetti, A.
    Martini, G.
    Avanzati, A.
    Franci, B.
    Marchini, E.
    Nuti, R.
    Lauria, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 149 - 149
  • [42] The effect of growth hormone on low-density lipoprotein cholesterol and lipoprotein(a) levels in familial hypercholesterolemia
    Tonstad, S
    Sundt, E
    Ose, L
    Hagve, TA
    Fruchart, JC
    Bard, JM
    Eden, S
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (11): : 1415 - 1421
  • [43] Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis
    Donner, MG
    Parhofer, KG
    Richter, WO
    Schwandt, P
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (07): : 881 - 886
  • [44] Oxidized low-density lipoprotein A plasma biomarker predicting stroke recurrence Comment
    Lorenzano, Svetlana
    NEUROLOGY, 2018, 91 (10) : 443 - 443
  • [45] Statins and low-density lipoprotein cholesterol levels
    Cohen, JS
    AMERICAN JOURNAL OF MEDICINE, 2003, 115 (01): : 74 - 75
  • [46] IS HYPERTRIGLYCERIDEMIC VERY LOW-DENSITY LIPOPROTEIN A PRECURSOR OF NORMAL LOW-DENSITY LIPOPROTEIN
    OSCHRY, Y
    EISENBERG, S
    DECKELBAUM, R
    OLIVECRONA, T
    ARTERIOSCLEROSIS, 1982, 2 (05): : A442 - A442
  • [47] Evaluation of Malondialdehyde Low-Density Lipoprotein Stratified by Low-Density Lipoprotein Cholesterol
    Moriyama, Kengo
    Takahashi, Eiko
    CLINICAL LABORATORY, 2017, 63 (7-8) : 1179 - 1186
  • [48] IS HYPERTRIGLYCERIDEMIC VERY LOW-DENSITY LIPOPROTEIN A PRECURSOR OF NORMAL LOW-DENSITY LIPOPROTEIN
    OSCHRY, Y
    OLIVECRONA, T
    DECKELBAUM, RJ
    EISENBERG, S
    JOURNAL OF LIPID RESEARCH, 1985, 26 (02) : 158 - 167
  • [49] Low-density lipoprotein and oxidised low-density lipoprotein: Their role in the development of atherosclerosis
    Hamilton, CA
    PHARMACOLOGY & THERAPEUTICS, 1997, 74 (01) : 55 - 72
  • [50] LOW-DENSITY LIPOPROTEIN RECEPTOR PATHWAY IN MAN - ITS ROLE IN REGULATING PLASMA LOW-DENSITY LIPOPROTEIN LEVELS
    PACKARD, CJ
    SHEPHERD, J
    ATHEROSCLEROSIS REVIEWS, 1983, 11 : 29 - 63